Clinical biomarkers and imaging for radiotherapy-induced cell death

Cancer and Metastasis Reviews

Volumn 27, Issue 3, 2008, Pages 471-480

  Verheij, Marcel ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Annexin V; Apoptosis; Biomarker; Cell death; Imaging; Radiotherapy

Indexed keywords

BIOLOGICAL MARKER; LIPOCORTIN 5; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; SPHINGOMYELIN;

APOPTOSIS; AUTOPHAGY; CANCER RADIOTHERAPY; CELL AGING; CELL DEATH; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; MITOSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

ANIMALS; CELL DEATH; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 47949118084     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-008-9131-1     Document Type: Review

References (63)

1. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57-70.
2. Kroemer, G., El-Deiry, W. S., Golstein, P., Peter, M. E., Vaux, D., Vandenabeele, P., et al. (2005). Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death. Cell Death and Differentiation, 12, 1463-1467.
3. Hengartner, M. O. (2000). The biochemistry of apoptosis. Nature, 407, 770-776.
4. Wang, X. (2001). The expanding role of mitochondria in apoptosis. Genes & Development, 15, 2922-2233.
5. Puthalakath, H., & Strasser, A. (2002). Keeping killers on a tight leash: Transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death and Differentiation, 9, 505-512.
6. Zong, W. X., Lindsten, T., Ross, A. J., MacGregor, G. R., & Thompson, C. B. (2001). BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes & Development, 15, 1481-1486.
7. Wei, M. C., Lindsten, T., Mootha, V. K., Weiler, S., Gross, A., Ashiya, M., et al. (2000). tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes & Development, 14, 2060-2071.
8. Desagher, S., Osen-Sand, A., Nichols, A., Eskes, R., Montessuit, S., Lauper, S., et al. (1999). Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. Journal of Cell Biology, 144, 891-901.
9. Antonsson, B., Montessuit, S., Sanchez, B., & Martinou, J. C. (2001). Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. Journal of Biological Chemistry, 276, 11615-11623.
10. Cheng, E. H., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., et al. (2001). BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Molecular Cell, 8, 705-711.
11. Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2, 183-192.
12. Datta, R., Kojima, H., Banach, D., Bump, N. J., Talanian, R. V., Alnemri, E. S., et al. (1997). Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis. Journal of Biological Chemistry, 272, 1965-1969.
13. Kataoka, T., Schröter, M., Hahne, M., Schneider, P., Irmler, M., Thome, M., et al. (1998). FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. Journal of Immunology, 161, 3936-3942.
14. Tepper, A. D., de Vries, E., van Blitterswijk, W. J., & Borst, J. (1999). Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis. Journal of Clinical Investigation, 103, 971-978.
15. Sentman, C. L., Shutter, C. L., Hockenberry, D., Kanagaa, O., & Korsmeyer, S. J. (1991). Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67, 879-888.
16. Strasser, A., Harris, A. W., Jacks, T., & Cory, S. (1994). DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell, 79, 189-192.
17. Miyashita, T., Kralewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., et al. (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9, 1799-1805.
18. Miyashita, T., & Reed, J. C. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80, 293-299.
19. Fei, P., Bernhard, E. J., & El-Deiry, W. S. (2002). Tissue-specific induction of p53 targets in vivo. Cancer Research, 62, 7316-7327.
20. Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., et al. (2003). p53 has a direct apoptogenic role at the mitochondria. Molecular Cell, 11, 577-590.
21. Friesen, C., Herr, I., Krammer, P. H., & Debatin, K. M. (1996). Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Medicine, 2, 574-577.
22. Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., et al. (1997). Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. Journal of Clinical Investigation, 99, 403-413.
23. Belka, C., Schmid, B., Marini, P., Durand, E., Rudner, J., Faltin, H., et al. (2001). Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene, 20, 2190-2196.
24. Zong, W. X., Ditsworth, D., Bauer, D. E., Wang, Z. Q., & Thompson, C. B. (2004). Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes & Development, 18, 1272-1282.
25. Sun, X., Li, Y., Li, W., Zhang, B., Wang, A. J., Sun, J., et al. (2006). Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway. Cell Cycle, 5, 2029-2035.
26. Takai, H., Tominaga, K., Motoyama, N., Minamishima, Y. A., Nagahama, H., Tsukiyama, T., et al. (2000). Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes & Development, 14, 1439-1447.
27. Ianzini, F., & Mackey, M. A. (1998). Delayed DNA damage associated with mitotic catastrophe following X-irradiation of HeLa S3 cells. Mutagenesis, 13, 337-344.
28. Blank, M., Lerenthal, Y., Mittelman, L., & Shiloh, Y. (2006). Condensin I recruitment and uneven chromatin condensation precede mitotic cell death in response to DNA damage. Journal of Cell Biology, 74, 195-206.
29. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., & Craig, R. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Research, 51, 6304-6311.
30. Wang, C. W., & Klionsky, D. J. (2003). The molecular mechanism of autophagy. Molecular Medicine, 9, 65-76.
31. Paglin, S., Hollister, T., Delohery, T., Hackett, N., McMahill, M., Sphicas, E., et al. (2001). A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Research, 61, 439-444.
32. Paglin, S., & Yahalom, J. (2006). Pathways that regulate autophagy and their role in mediating tumor response to treatment. Autophagy, 2, 291-293.
33. Levine, B., & Klionsky, D. J. (2004). Development by self-digestion: Molecular mechanisms and biological functions of autophagy. Developmental Cell, 6, 463-747.
34. Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G., et al. (2006). Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell, 10, 51-64.
35. Kelekar, A. (2005). Autophagy. Annals of the New York Academy of Sciences, 1066, 259-271.
36. Campisi, J. (2000). Cancer, aging and cellular senescence. In Vivo, 14, 183-188.
37. Roninson, I. B. (2003). Tumor cell senescence in cancer treatment. Cancer Research, 63, 2705-2715.
38. Verheij, M., van Blitterswijk, W. J., & Bartelink, H. (1998). Radiation-induced apoptosis: The ceramide-SAPK signaling pathway and clinical aspects. Acta Oncológica, 37, 575-581.
39. Chapman, J. D., & Anderson, P. R. (1999). Predicting and overcoming the radioresistance of individual tumors. International Journal of Radiation Oncology, Biology, Physics, 44, 477-479.
40. Ong, F., Moonen, L. M. F., Gallee, M. P. W., ten Bosch, C., Zerp, S. F., Hart, A. A. M., et al. (2001). Prognostic factors in transitional cell cancer of the bladder: An emerging role for Bcl-2 and p53. Radiotherapy and Oncology, 61, 169-175.
41. Gerke, V., & Moss, S. E. (2002). Annexins: From structure to function. Physiological Reviews, 82, 331-371.
42. Andree, H. A., Stuart, M. C., Hermens, W. T., Reutelingsperger, C. P., Hemker, H. C., Frederik, P. M., et al. (1992). Clustering of lipid-bound annexin V may explain its anticoagulant effect. Journal of Biological Chemistry, 267, 17907-17912.
43. Ahn, N. G., Teller, D. C., Bienkowski, M. J., McMullen, B. A., Lipkin, E. W., & de Haen, C. (1988). Sedimentation equilibrium analysis of five lipocortin-related phospholipase A2 inhibitors from human placenta. Evidence against a mechanistically relevant association between enzyme and inhibitor. Journal of Biological Chemistry, 263, 18657-18663.
44. van Heerde, W. L., de Groot, P. G., & Reutelingsperger, C. P. (1995). The complexity of the phospholipid binding protein Annexin V. Thrombosis and Haemostasis, 73, 172-179.
45. Sun, J., Bird, P., & Salem, H. H. (1993). Interaction of annexin V and platelets: Effects on platelet function and protein S binding. Thrombosis Research, 69, 289-296.
46. Sugimura, M., Donato, R., Kakkar, V. V., & Scully, M. F. (1994). Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces. Blood Coagulation & Fibrinolysis, 5, 365-373.
47. 99mTc annexin V. Journal of Nuclear Medicine, 40, 184-191.
48. Hofstra, L., Liem, I. H., Dumont, E. A., Boersma, H. H., van Heerde, W. L., Doevendans, P. A., et al. (2000). Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet, 356, 209-212.
49. Blankenberg, F. G., Robbins, R. C., Stoot, J. H., Vriens, P. W., Berry, G. J., Tait, J. F., et al. (2000). Radionuclide imaging of acute lung transplant rejection with annexin V. Chest, 117, 834-840.
50. Lorberboym, M., Blankenberg, F. G., Sadeh, M., & Lampl, Y. (2006). In vivo imaging of apoptosis in patients with acute stroke: Correlation with blood-brain barrier permeability. Brain Research, 1103, 13-19.
51. Belhocine, T., Steinmetz, N., Hustinx, R., Bartsch, P., Jerusalem, G., Seidel, L., et al. (2002). Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clinical Cancer Research, 8, 2766-2774.
52. Haas, R., de Jong, D., Valdés Olmos, R. A., Zerp, S. F., van den Heuvel, I., Bartelink, H., et al. (2004). In vivo imaging of radiation-induced apoptosis by 99mTc-annexin-V scintigraphy in follicular lymphoma patients. International Journal of Radiation Oncology, Biology, Physics, 59, 782-787.
53. Dubray, B., Breton, C., Delic, J., Klijanienko, J., Maciorowski, Z., Vielh, P., et al. (1997). In vitro radiation-induced apoptosis and tumour response to radiotherapy: A prospective study in patients with non-Hodgkin lymphomas treated by low-dose irradiation. International Journal of Radiation Biology, 72, 759-760.
54. Verheij, M., & Bartelink, H. (2000). Radiation-induced apoptosis. Cell and Tissue Research, 301, 133-142.
55. Kartachova, M., Haas, R. L. M., Valdés Olmos, R. A., Hoebers, F. J. P., van Zandwijk, N., & Verheij, M. (2004). In vivo imaging of apoptosis by 99m-annexin V scintigraphy: Visual analysis in relation to treatment response. Radiotherapy and Oncology, 72, 333-339.
56. 99mTc Hynic-rh-Annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. Journal of Clinical Oncology, 25, 2534-2539.
57. Kartachova, M., Verheij, M., van Eck, B., Hoefnagel, K., & Valdés Olmos, R. (2005). Methodological aspects and applications of in vivo imaging of apoptosis in oncology: An illustrative review. Current Medical Imaging Review, 1, 221-228.
58. 99mTc hynic-rh-annexin V SPECT and CT image fusion. European Journal of Nuclear Medicine and Molecular Imaging, 33, 893-899.
59. Faust, A., Wagner, S., Law, M. P., Hermann, S., Schnockel, U., Keul, P., et al. (2007). The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F] fluoroethoxy)-benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin [18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 51, 67-73.
60. 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 30, 879-887.
61. Borst, G. R., Belderbos, J. S., Boellaard, R., Comans, E. F., De Jaeger, K., Lammertsma, A. A., et al. (2005). Standardised FDG uptake: A prognostic factor for inoperable non-small cell lung cancer. European Journal of Cancer, 41, 1533-1541.
62. Martinet, W., De Meyer, G. R., Andries, L., Herman, A. G., & Kockx, M. M. (2006). Detection of autophagy in tissue by standard immunohistochemistry: Possibilities and limitations. Autophagy, 2, 55-57.
63. Itahana, K., Campisi, J., & Dimri, G. P. (2007). Methods to detect biomarkers of cellular senescence: The senescence-associated beta-galactosidase assay. Methods in Molecular Biology, 371, 21-31.